Application of small molecule compound in treatment of metastatic testicular spermatogonoma
By using small molecule compounds of rutin, ICG-001 and doxorubicin, CTLA4, SNX17 and TMX1 gene expression, respectively, the existing problem of poor efficacy in the treatment of metastatic testicular senogenoma was solved, and tumor cells were significantly inhibited The proliferation and invasion ability provide an effective treatment plan.
Patent Information
- Application Number
- CN202410988947.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-23
- Publication Date
- 2024-11-12
AI Technical Summary
The existing methods for treating metastatic testicular semenoma are limited in effect, especially in platinum-resistant diseases with low survival rates, and targeted treatments have not yet effectively inhibit the proliferation and invasion of tumor cells.
Using three small molecule compounds, rutin, ICG-001 and doxorubicin, drugs for the treatment of metastatic seminoma were prepared by upregulating CTLA4 and downregulating the expression of SNX17 and TMX1 genes, and inhibiting the proliferation of tumor cells. and invasion ability.
It significantly inhibits the proliferation, migration and invasion ability of Tcam-2 cells in the testicular semenoma cell line, providing an effective treatment for metastatic testicular semenoma.
Smart Images

Figure HDA0004958319950000011 
Figure HDA0004958319950000021 
Figure HDA0004958319950000022
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of genetic engineering, and specifically relates to the application of small molecule compounds in treating metastatic testicular seminoma. Background Art
[0002] Testicular seminoma is one of the most common types of cancer in young men, accounting for almost half of all testicular germ cell tumors. The vast majority of patients with seminoma are cured by current treatment concepts, including orchiectomy, radiotherapy, and / or platinum-based chemotherapy. However, patients with these platinum-refractory diseases that metastasize after high-dose chemotherapy have poor survival. Given the high density of immune cells commonly found in seminoma, immune checkpoint inhibitors could theoretically be a therapeutic option for these tumors. Indeed, clinical responses and nonresponses have been reported for advanced germ cell cancers after treatment with nivolumab or pembrolizumab, and clinical trials systematically evaluating these agents in platinum-resistant germ cell tumors are ongoing. The clinical success of inhibitors targeting the PD-1 / PD-L1 checkpoint has been striking in many cancers, and early studies have reported a prognostic role for tumor-infiltrating lymphocytes expressing PD-L1 in seminoma specimens. In addition, it is promising that the use of combination drugs targeting not only single, but several immune checkpoint receptors may further improve treatment efficacy. CTLA-4, like PD-1, plays a crucial role in suppressing tumor-directed immune responses and may therefore be a suitable and relevant target for new immunomodulatory therapies. In addition, SNX17 and TMX1, as immune-related genes, have been reported to play a significant role in regulating immune cell function. Summary of the invention
[0003] Purpose of the invention: The technical problem to be solved by the present invention is to provide an application of a small molecule compound in the treatment of metastatic testicular seminoma.
[0004] The technical problem to be solved by the present invention is that the molecular compounds of rutin, ICG-001 and doxorubicin can selectively target CTLA4, SNX17 and TMX1 respectively, thereby inhibiting the proliferation and invasion ability of seminoma tumor cells.
[0005] Technical solution: To solve the above technical problems, the present invention provides the use of small molecule compounds in the preparation of drugs for treating metastatic seminoma, wherein the small molecule compounds include one or more of rutin, ICG-001 or doxorubicin.
[0006] Wherein, the rutin treats metastatic seminoma by upregulating the expression of the CTLA4 gene.
[0007] Among them, the ICG-001 treats metastatic seminoma by downregulating the expression of the SNX17 gene.
[0008] Wherein, the doxorubicin treats metastatic seminoma by downregulating the expression of TMX1 gene.
[0009] The present invention also provides the use of a reagent for detecting the expression amount of CTLA4, SNX17 and / or TMX1 genes in preparing a reagent or a kit for diagnosing metastatic seminoma.
[0010] The present invention also provides the use of a drug for up-regulating CTLA4 and down-regulating the expression of SNX17 and / or TMX1 genes in the preparation of a drug for treating metastatic seminoma.
[0011] Wherein, the drug includes one or more of rutin, ICG-001 or doxorubicin.
[0012] Wherein, the medicine is a single-component preparation or a compound preparation.
[0013] Wherein, the drug dosage forms include injections, solutions, powders, tablets, pills, aerosols, ointments, emulsions or capsules.
[0014] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages: The present invention obtains and proves for the first time that three molecular compounds, namely rutin, ICG-001 and doxorubicin, significantly inhibit the proliferation, migration and invasion ability of testicular seminoma cell line Tcam-2 cells, thereby inhibiting the proliferation and invasion ability of seminoma tumor cells. Therefore, the compounds of the present application can be effectively used to treat metastatic testicular seminoma. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 Molecular docking and dynamics simulation of three pairs of molecular protein complexes. (a) Free energy landscape and molecular docking of the binding simulation between molecular compound ICG-001 and protein SNX17, doxorubicin and TMX1 (b), and rutin and CTLA4 (c). (df) Gyrate diagrams of the three complexes.
[0016] Figure 2 (a) shows the hydrogen bonds (HBond) of three pairs of protein molecules. Figure 2 (b) Protein surface area (SASA).
[0017] Figure 3 IF staining of metastatic and non-metastatic seminoma samples, including 33 immune-related genes (orange), CD22 (green), CD3 (red), CD27 (light green), and Vimentin (yellow).
[0018] Figure 4(a) The difference in mRNA and protein expression after treatment with the corresponding molecular compounds at IC50 effective concentration. Cloning (b), cell scratch (c) and transwell assay (d) of Tcam-2 cells treated with molecular compounds. (e) Protein expression of epithelial-mesenchymal transition (EMT) markers (e-cad, N-cad, Vimentin) in Tcam-2 cells treated with molecular compounds. DETAILED DESCRIPTION
[0019] The technical solution of the present invention is further described below in conjunction with the accompanying drawings.
[0020] Example 1
[0021] 1. Molecular compound screening and docking
[0022] Protein crystal structures of three immune-related genes were downloaded from the PDB data set. Candidate molecular structures were downloaded from the Pubchem data set. MOE software (version 2019.0102) was used to prepare protein structures and perform docking scoring. In brief, the active site of each enzyme was determined using the MOEα site finder. The ligand molecules were then positioned within the site using the triangular matcher method and ranked using the London dG scoring function. Subsequently, the ten best poses (30 by default) were selected and further refined by energy minimization within the binding pocket. After refinement, they were rescored using the GBVI / WSA dG scoring function. Potential molecules that can upregulate CTLA4 and downregulate TMX1 and SNX17 were obtained from the Pubchem database. After docking with the molecular database, ICG-001, rutin, and doxorubicin showed the lowest binding energy (ΔGMMGBSA=30.48, -27.39, -17.23KCal / Mol) and most of the connecting bonds with the corresponding protein complexes. Free energy landscapes provide insight into the interactions and energy distribution between molecules within a system, helping to understand interaction characteristics, conformational states, and stabilities. This information has proven to be invaluable in designing molecular interaction mechanisms and materials. In this case, the landscape is delineated by two key metrics: RMSD (root mean square deviation) and R(g) (radius of gyration). Throughout the simulation, we identified low energy regions indicating that the molecules adopt various interaction modes or conformations to achieve the minimum energy state. The root mean square deviation (RMSD) is used as a metric to assess protein structural changes. In this simulation, we calculated the RMSD values between the protein and the small molecule and visualized the RMSD trends ( Figure 1Our findings show that within the first 100 nanoseconds of the three simulations, the RMSD values between the protein and the small molecule exhibit considerable variability before gradually stabilizing. Throughout the simulations, the RMSD values remained within a narrow range, indicating a stable binding between the protein and the small molecule.
[0023] 2. Molecular dynamics simulation
[0024] This molecular dynamics simulation uses Gromacs2022.3 version software for molecular dynamics simulation. AmberTools22 is used for small molecule pretreatment to add GAFF force field to small molecules. Gaussian 16W is used to hydrogenate small molecules and calculate RESP potential operations. The potential data will be added to the molecular dynamics system topology file. The simulation conditions are carried out at a static temperature of 300K and normal pressure (1Bar). The force field uses Amber99sb-ildn, the solvent is water molecules (Tip3p water model), and the total charge of the simulation system is neutralized by adding an appropriate number of Na+ ions. The molecular dynamics simulation system first uses the steepest descent method to minimize energy, and then performs 100,000 steps of isothermal isochoric ensemble (NVT) equilibrium and isothermal isobaric ensemble (NPT) equilibrium, respectively, with a coupling constant of 0.1ps and a duration of 100ps. Finally, the free molecular dynamics simulation is run, which consists of 5,000,000 steps, a step size of 2fs, and a total duration of 100ns. After completing the simulation, the software's built-in tools were used to analyze the trajectory and calculate the root mean square deviation (RMSD), root mean square fluctuation (RMSF) of each amino acid trajectory, protein gyration radius, binding free energy (MMGBSA), free energy profile and other data. Gyrate can be used as an indicator to evaluate the overall compactness of the protein. In this simulation, the Gyrate between the protein and the small molecule was calculated. Figure 1 d~f). Our analysis shows that after binding with small molecules, the Gyrate of the protein decreases compared to the single protein molecule, indicating that the binding of small molecules leads to an increase in the compactness of the protein molecule. The distance distribution function and hydrogen bond evaluation in the simulation ( Figure 2 a) and other analyses can further clarify the rationality of their interaction. Based on these findings, it can be inferred that the interaction between protein and small molecules is stable. In addition, the binding of small molecules induces compaction of protein molecules, reducing the surface area ( Figure 2 b) and promote the formation of a large number of hydrogen bonds with small molecules. Through the pre-selected molecular compound library, all molecular compounds are docked with the corresponding proteins, and molecular dynamics is performed on the molecular compounds with the best binding energy and binding bonds.
[0025] Ligand and receptor Binding Energy Score Combination Key ICG-001 and SNX17 -7.9085 3 Doxorubicin and TMX1 -6.4081 5 Rutin and CTLA-4 -7.8349 7
[0026] Example 2
[0027] 1. Sample collection
[0028] Seminoma samples and adjacent normal tissues were collected from specimens of 38 patients (mean age: 34±4 years, range: 21-43 years) at the First Affiliated Hospital of Nanjing Medical University and Nanjing Jinling Hospital between 2011 and 2021. These patients underwent orchiectomy and were subsequently diagnosed with testicular seminoma based on postoperative pathology. Postoperative metastasis was found in 12 cases, including local metastasis in 7 cases, new primary tumors in 4 cases, and distant metastasis in 1 case. Samples for RNA extraction were immediately frozen in liquid nitrogen and stored at -80°C. Samples for immunohistochemical analysis were fixed in formalin. The study design and protocol were ethically approved by the Ethics Committee of Jinling Hospital, and informed consent was obtained from all participants.
[0029] 2. RNA extraction, reverse transcription and qRT-PCR
[0030] Total RNA was extracted from testicular tissue and cell lines using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Total RNA was reverse transcribed into complementary DNA (cDNA) using HiScript II (Vazyme, Shanghai, China). qRT-PCR was performed on an ABI 7900 system (Applied Biosystems, Carlsbad, CA, USA) using SYBR Green I (Vazyme, Shanghai, China) with the following primers: CTLA4-Forward: 5'-GCCCTGCCTCGTTT-3'; CTLA4 Reverse: 5'-GGTTGCGCACAGACTTCA-3'. SNX17 Forward: 5'-CGCTACGTGGCCTATACAT-3'; SNX17 Reverse: 5'-CAATGGGTCTTGCCGAACAG-3'. TMX1 forward: 5’-TTGCGAAAGTAG ATGTCACAGAG-3’; TMX1 reverse: 5’-CTGATAGCGCCTAATTCACCAT3’.
[0031] 3. Cell culture
[0032] The Tcam-2 cell line was derived from a testicular seminoma obtained from the Urology Department of the Run Run Shaw Hospital, Zhejiang University School of Medicine. The cells were cultured in DMEM medium (Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS) at 37°C and 5% CO2.
[0033] 4. Antibodies and Reagents
[0034] Primary antibodies were obtained from: mouse anti-CTLA4 (Santa Cruz, sc376016), rabbit anti-SNX17 (abcam, ab223046), rabbit anti-TMX1 (abcam, ab244263), anti-GAPDH, CD27, CD22, CD3, Vimentin, E-cad, N-cad were all from Servicebio technology. Secondary antibodies including anti-mouse IgG, anti-rabbit IgG, Alexa Fluor secondary antibodies (spectrum 440 aqueous solution, 488 green, 546 red, 594 orange, 647 yellow) were also obtained from Servicebio technology. Rutin, ICG-001 and doxorubicin were obtained from Selleck chem.
[0035] 5. Immunofluorescence (IF)
[0036] To evaluate the differences in the expression patterns of IRSG and immune cell infiltration patterns between metastatic and non-metastatic seminoma tissues, IF assays were performed. The specific experimental steps are as follows:
[0037] For tissues representing metastatic and non-metastatic seminoma, coverslips were first washed three times in PBS and then fixed in 4% paraformaldehyde for 15 minutes. Subsequently, permeabilization was achieved by treating the slides with 0.5% Triton X-100 for 20 minutes at room temperature, followed by three PBS washes and blocking with 2% BSA for 30 minutes. The slides were then incubated with the appropriate primary antibodies overnight at 4°C, followed by incubation with secondary antibodies for 2 hours at room temperature. Nuclei were counterstained with DAPI and slides were scanned with a 3DHISTECH scanner (Pannoramic MIDI).
[0038] The experimental results can be found in Figure 3 , notably, elevated expression of CTLA4 was observed in non-metastatic seminoma tissues, along with increased fluorescence signals of CD3, a marker for gamma-delta T cells. In contrast, TMX1 and SNX17 showed upregulation in metastatic seminoma tissues, consistent with a decrease in infiltration of memory B cells (CD27). Moreover, infiltration of naive B cells (CD22) mirrored the expression pattern of TMX1. Furthermore, upregulation of vimentin, an indicator of cell invasion capacity, was noted in metastatic patients, suggesting increased invasive and metastatic potential, indicating a higher rate of metastasis.
[0039] In summary, we found that the expression of CD3, a cell marker of γ-ΔT cells, was positively correlated with the expression of CTLA4, leading to a decrease in the expression level of vimnentin and an increase in the metastasis rate. In addition, the infiltration level of naive B cells was positively correlated with TMX1, while the infiltration level of memory B cells was negatively correlated with TMX1-SNX17. Therefore, the increased expression levels of TMX1 and SNX17, coupled with the increase in the infiltration of naive B cells and the decrease in the infiltration of memory B cells, were associated with an increased metastasis rate in patients.
[0040] 6. Cell proliferation and cloning experiments
[0041] To assess cell proliferation, Tcam-2 cells were seeded in 96-well plates at a density of 2×10^3 cells per well. Subsequently, the CCK-8 system (Dojindo, Japan) was added to each well at 0, 1, 2, 3, and 4 days of culture according to the instructions. Absorbance readings were read at 450nm using a microplate reader (Tecan, Switzerland) to determine cell viability. For colony formation assays, approximately 1×10^3 cells were seeded in six-well culture dishes and treated with DMSO, rutin, ICG-001, and doxorubicin, respectively. After two weeks of culture, the colonies were fixed with paraformaldehyde, stained with 0.1% crystal violet, and subsequently imaged and counted. The IC50 values of Tcam-2 cell treatment were determined, Figure 4 a As can be seen, the IC50 value of rutin is 38.19μM, the IC50 value of ICG-001 is 10.96μM, and the IC50 value of doxorubicin is 0.3994μM. This leads to a significant inhibition of cell proliferation. The most significant differences were observed at 2 days, 4 days, and 3 days, respectively, compared with the control DMSO group. After treatment with rutin, both the mRNA and protein expression levels of CTLA4 were upregulated. In contrast, treatment with doxorubicin and ICG-001 led to downregulation of the mRNA and protein expression levels of TMX1 and SNX17, respectively. With the application of the three molecular treatments, the clone formation of Tcam-2 cells can be seen in Figure 4 b, The colony number of Tcam-2 cells was reduced.
[0042] 7. Cell scratch and Transwell assay
[0043] Tcam-2 cells were seeded into six-well plates at a density of 3 × 10^5 cells per well and cultured until a density of 90%–100% was reached. After scratching with a 10 μL pipette tip, the wells were washed twice with PBS to eliminate cell debris and residual serum. Subsequently, the cells were cultured in serum-free DMEM for another 12 h. The scratch edges were photographed using DP-BSW software (10× objective) 12 h after injury and measured using ImageJ software. For transwell assays, cells were seeded at a density of 1 × 10^5 cells in 200 μL serum-free medium onto an upper chamber with a pore size of 8 mm, which was coated or not coated with 50 μL of Matrigel (BD Biosciences). The lower chamber was filled with DMEM containing 20% FBS as a chemoattractant. After incubation at 37°C for 12 h for migration and 48 h for invasion, cells that migrated to the lower side of the membrane were fixed in 4% paraformaldehyde for 30 min and subsequently stained with 2% crystal violet. Non-migrated or non-invading cells were gently removed, and cells that migrated to the outer chamber were counted in five representative fields at 200x magnification. Cells treated with the three molecules showed weaker healing ability than the control group, especially doxorubicin ( Figure 4 c). Rutin, ICG-001 and doxorubicin can significantly inhibit the migration and invasion ability of Tcam-2 cells ( Figure 4 d).
[0044] 8. Western blotting
[0045] Cells treated with RIPA lysate (Beyotime Biotechnology, Shanghai, China) lysate reagent were used. The harvested proteins were quantified using a BCA kit (Beyotime Biotechnology), separated on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and transferred to polyvinylidene fluoride (PVDF) membranes (Sigma-Aldrich, St.Louis, MO). The membranes were then blocked for 2 hours in Tris buffered saline (TBS) containing 5% skim milk. After incubation overnight with an antibody at 4°C, the membranes were washed three times with TBS containing 0.1% Tween 20 (TBST). Subsequently, they were incubated at room temperature for 2 hours with a secondary antibody solution. After another round of washing, the signal was detected using a chemiluminescence system and analyzed using Image Lab software.
[0046] Western blotting results can be found in Figure 4 a and 4e, rutin, ICG-001 and doxorubicin can simultaneously upregulate E-cad and downregulate vimentin and N-cad ( Figure 4e)。
Claims
1. Use of a small molecule compound in the preparation of a drug for treating metastatic seminoma, characterized in that: The small molecule compound includes one or more of rutin, ICG-001 or doxorubicin.
2. The use according to claim 1, characterized in that: Rutin upregulates CTLA4 Gene expression in the treatment of metastatic seminoma.
3. The use according to claim 1, characterized in that: ICG-001 downregulates SNX17 Gene expression in the treatment of metastatic seminoma.
4. The use according to claim 1, characterized in that: The doxorubicin downregulates TMX1 Gene expression in the treatment of metastatic seminoma.
5. Detection CTLA4 , SNX17 and / or TMX1 The invention relates to an application of a reagent for measuring the expression level of a gene in preparing a reagent or a kit for diagnosing metastatic seminoma.
6. Upward adjustment CTLA4 , down SNX17 and / or TMX1 The invention discloses an application of a drug for regulating the expression level of a gene in preparing a drug for treating metastatic seminoma.
7. The use according to claim 6, characterized in that: The drugs include rutin, ICG-001 or doxorubicin.
8. The use according to claim 1 or 6, characterized in that: The medicine is a single-component preparation or a compound preparation.
9. The use according to claim 1 or 6, characterized in that: The pharmaceutical dosage forms include injections, solutions, powders, tablets, pills, aerosols, ointments, emulsions or capsules.
